FDA-approved amyloid-targeting therapies — lecanemab (Leqembi) and donanemab (Kisunla) receiving FDA approval for early AD treatment — have fundamentally transformed Alzheimer's diagnostics from a primarily academic exercise toward a clinically necessary component of treatment pathway qualification, with the Alzheimer's Disease Diagnostic Market reflecting the treatment-driven diagnostic market transformation.

Diagnosis prerequisite for treatment access — FDA labels for lecanemab and donanemab requiring confirmation of amyloid pathology through either amyloid PET or CSF biomarker testing before treatment initiation — have created immediate commercial demand for biomarker testing linked to treatment eligibility determination. The treatment pathway creating a diagnostic prerequisite has transformed AD biomarker testing from optional characterization to clinically mandatory gateway for patients seeking treatment.

Lecanemab and donanemab treatment monitoring diagnostics — the MRI ARIA safety monitoring, cognitive endpoint testing, and periodic biomarker re-assessment built into the treatment protocols for amyloid-targeting therapies — create ongoing diagnostic utilization throughout the treatment course rather than one-time pre-treatment assessment. The ARIA monitoring MRI requirement during initial treatment phases creates systematic brain imaging demand directly linked to treatment volume.

Healthcare system readiness for AD diagnosis scale-up — the challenge of building adequate AD diagnostic infrastructure (neurologists, memory specialists, imaging capacity, laboratory biomarker testing) to serve the large population with mild cognitive impairment who may be candidates for treatment — represents the implementation challenge that biomarker testing commercial adoption must address. The estimated one to two million US patients potentially eligible for amyloid-targeting therapy greatly exceeds current AD specialist and imaging capacity, requiring healthcare system adaptation.

Do you think the current healthcare system infrastructure is adequate to provide timely AD biomarker diagnosis to all potentially eligible treatment candidates, and what bottlenecks most urgently require capacity expansion?

FAQ

Why do Alzheimer's treatments require biomarker confirmation? FDA-approved amyloid-targeting antibodies (lecanemab, donanemab) specifically target amyloid plaques; treating patients without confirmed amyloid pathology would expose them to ARIA risks without potential benefit since the mechanism requires amyloid to target; clinical trial eligibility required amyloid PET or CSF biomarker positivity; FDA labels reflect this trial design; confirmatory biomarker testing ensures appropriate patient selection maximizing benefit-risk ratio; blood-based biomarkers may eventually streamline this confirmation step.

What is the difference between lecanemab and donanemab? Lecanemab (Leqembi, Biogen/Eisai) targets protofibrils and fibrils of amyloid-beta, given biweekly IV infusion; donanemab (Kisunla, Eli Lilly) targets a specific truncated form of amyloid in plaques (pyroglutamate Aβ), given monthly IV infusion; both demonstrated significant amyloid clearance and modest but statistically significant clinical slowing in phase III trials; donanemab can be discontinued after achieving amyloid clearance (negative amyloid PET), potentially limiting treatment duration; ARIA rates are comparable between the two treatments.

#AlzheimersDiagnostic #LecanemabDiagnostics #ADtreatmentDiagnostics #AmyloidTargeting #AlzheimersTreatment Diagnostics #ADbiomarkerTreatment